Reaction of 2‐chloromethylbenzimidazole with known intermediates (i – iii), prepared from diaminoguanidine hydrochloride with salicylaldehyde, 5‐bromo‐salicylaldehyde or 3,5‐di‐tert‐butylsalicylaldehyde, led to the formation of benzimidazole appended new ligands, H4L1–H4L3 (I−III). The homogeneous nitrogen‐bridged symmetrical binuclear complexes, [(MoVIO2)2(L1)(H2O)2] (1), [(MoVIO2)2(L2)(H2O)2] (2) and [(MoVIO2)2(L3)(MeOH)2] (3) and mononuclear complexes, [MoVIO2(H2L1)(MeOH)] (4), [MoVIO2(H2L2)(H2O)] (5) and [MoVIO2(H2L3)(MeOH)] (6).have been isolated by reacting these ligands. The corresponding binuclear heterogeneous compounds [(MoVIO2)2(L1)(DMF)2]@PS (PS‐1), [(MoVIO2)2(L2)(DMF)2]@PS (PS‐2) and [(MoVIO2)2(L3)(DMF)2]@PS (PS‐3) have been obtained by immobilization of 1−3 onto chloromethylated polystyrene beads. All synthesized ligands, homogeneous as well as heterogeneous supported compounds have been characterized well. Heterogeneous compounds (PS‐1−PS‐3) have further been studied by microwave plasma atomic emission spectroscopy, X‐ray photoelectron spectroscopy, and field emission scanning electron microscopy along with energy dispersive spectroscopy. All compounds were explored for catalytic applications to one‐pot multicomponent reactions (MCRs) for efficient synthesis of biologically active 2‐amino‐3‐cyano‐4H‐chromenes/pyrans (21 examples). Optimizing various reaction parameters helped in achieving as high as 97% yields of products. Though, only half equivalent of the binuclear complexes (1‐3) was required compared to mononuclear analogues (4‐6) to achieve comparable yields, heterogeneous catalysts have an added advantage due to their stability and recyclability. Suitable reaction mechanism has also been proposed based on isolated intermediate(s).